Article

FDA Enforcement Part 4: What FDA Evaluates After Your Form 483 Response

PTPomio teamOctober 27, 20265 min read

TL;DR

After a Form 483, most of what FDA says it weighs is the pharmacy's response: its evidence, its scope, and whether the fix will last.

FDA's Regulatory Procedures Manual lists seven factors for deciding whether to issue a Warning Letter. Three are about the past and the product. The other four are about the response: whether the correction is adequate and covers the whole problem, whether it is documented, whether its timeline fits, and whether it will last.

In the Michigan Medicine letter from Part 1, the response gaps FDA named were about documentation and scope.

Pick one corrective action your pharmacy completed this year. Can you show what was done, who owned it, and how you know it is still being done?

What a Form 483 Response Is For

The written response is the pharmacy's one structured chance to shape what FDA decides next.

FDA issues a Form 483 at the end of an inspection when investigators observed conditions that, in their judgment, may violate the Federal Food, Drug, and Cosmetic Act. FDA's own FAQ says the form is not a final agency determination.

FDA encourages the pharmacy to respond in writing with its corrective action plan and then carry that plan out.

In a 2009 notice, FDA said that if a response arrives within 15 business days after the Form 483 is issued, it would review the response in detail before deciding whether to issue a Warning Letter.

What FDA Says It Weighs

Four of the seven factors FDA weighs are about the response, which is the part the pharmacy controls.

FDA's Regulatory Procedures Manual lists the factors FDA considers when a pharmacy is correcting the problems or has promised to, and FDA is deciding whether to issue a Warning Letter. Paraphrased, they are:

The pharmacy's compliance history
The nature of the violation
The risk the product presents
The adequacy and scope of the corrective action
Whether documentation of the correction was provided
Whether the timelines are appropriate
Whether the correction is likely to be sustained

The first three are about the past and the product, and a response cannot change them. The last four are about the response itself.

The same section says promised or ongoing corrections generally do not prevent a Warning Letter, so a plan without evidence counts for little.

The Michigan Letter, Read as a Checklist

Each response gap in the Michigan letter falls under one of two factors: documentation or scope.

Part 1 covered the University of Michigan Warning Letter. Read against the list above, FDA's comments on the response map almost one to one.

Retraining described, training records not provided: documentation.
Transfer procedure improved, but the procedure did not fully explain how other surfaces would be sanitized: scope.
Repairs reported, supporting documentation not provided: documentation.
Two observations not addressed: scope.

None of FDA's comments said a correction was wrong. Each said a correction was not shown or did not cover the whole observation.

This is what I want you to take from the letter: the gaps were in the part of the response the medical center controlled.

What the Enforcement Set Can Show

The enforcement set cannot show which responses work, because it does not contain the responses.

The set holds 406 Form 483s and only 5 Warning Letters. That is too few letters to say what usually leads to one.

What the set does show is how much a response has to cover. Of the 385 Form 483s with an observation count, the median lists 5 observations. About one in eight lists 10 or more.

What a Response Needs to Contain

For each observation, a response should cover the four factors the pharmacy controls.

Adequacy. State what was found, what the root cause was, and what changed. A fix that addresses the symptom without the cause reads as inadequate.
Scope. Say whether the same condition could exist elsewhere: other rooms, other products, other staff, other records. Then say what you checked.
Documentation. Attach the record, because the people who read the response were not at the inspection. Send the revised procedure, the training roster with dates and signatures, the certification report, the repair invoice, the photograph.
Timeline and sustainability. For work not yet finished, give a date and an owner. For finished work, name the recurring task that keeps it in place and who reviews it.

Each observation should leave a small file behind: the observation, the owner, the correction, the evidence, the review, and the recurring control.

That file answers the five questions from Part 1: what was expected, who owned it, when it occurred, what supports completion, and who reviewed it.

What Transfers to a Smaller Pharmacy

A smaller pharmacy's response needs the same file as Michigan's did.

FDA's guidance to states says state boards carry day-to-day oversight of most compounders. An independent 503A pharmacy is more likely to see a board inspector than an FDA investigator.

A response that says "retrained staff" with no training roster has the same gap the Michigan response had, whether a board or FDA reads it.

Build the file as the work happens, not when the letter arrives. A corrective action with an owner, a due date, attached evidence, and a review step is already most of a response.

If it isn't documented, it didn't happen.

Next in the Series

Part 5 follows the pharmacies in the set from a Form 483 to whatever came next: an Untitled Letter, a state hand-off, a Warning Letter, or nothing at all.

Sources and Scope

The factors listed are paraphrased from FDA's Regulatory Procedures Manual (section 4-1-3) and are not the only considerations FDA applies. Document counts come from Pomio's parsed set of 680 FDA compounding enforcement documents (2016 through 2026). The set does not include pharmacies' written responses, so nothing here measures how FDA judged a particular response. The work-package structure is Pomio's synthesis, not an FDA requirement. This article is educational and is not legal advice.

Back to all posts